Free · Substack Oct 14, 2026 · 2 min read

End-of-day recap

Hotter-than-expected inflation raised Fed hike odds and drove a tech selloff amid concerns over financing the AI buildout.

End-of-day recap
QA HOLD · End-of-Day Market Recap · EOD Market Recap, Oct 14, 2026 · Wed, Oct 14

A hotter-than-expected inflation print drove today's session. Rate-hike odds rose, tech sold off, and high-multiple hardware names took some of the hardest hits.

The S&P 500 fell 1.11% to 7,718.94 and the Nasdaq dropped 1.88% to 26,692.87. The 10-year Treasury yield closed at 5.19% and the 2-year at 4.82%. September CPI came in at 3.7% versus 3.6% expected, with core at 2.6% versus 2.5%, raising odds of an October 28 Fed hike. Chicago Fed President Austan Goolsbee called the print discouraging but said more data are needed.

Healthcare led at +2.53% and technology lagged at -2.98%. Reuters tied the rotation to the inflation data and to worries about how the AI buildout gets financed.

Jefferies raised its Microsoft price target to $650 from $575.

UBS assumed Regeneron with a Buy rating, up from Neutral, and a $978 target.

Scotiabank initiated Diamondback Energy at Outperform with a $250 target, as part of a broad initiation wave across E&P.

Everpure fell as much as 10.39% intraday and closed down 9.88% at $141.46, barely off the low, then slid another 3.41% after hours to $136.63. Reports cited rate pressure on tech, profit-taking after a sharp run, and insider-sale disclosures.

BPRE director Ramin Kamfar has been buying shares. The fund closed down 1.80% at $12.55 and traded at $12.84 after hours.

CoreWeave CEO Mike Intrator called the market's reaction to the company's data center borrowing irrational in a staff memo.

Wolfspeed investors are weighing its October 7 conditional $1.5 billion Department of War loan commitment against a prospectus covering up to 58.15 million resale shares and warrants.

Skydance shares began trading without entitlement to roughly 471 million warrants. Class B holders received the warrants after the completed Warner Bros. Discovery acquisition.

Liquidia settled its Yutrepia patent litigation with United Therapeutics. BTIG upgraded the stock to Buy with a $70 target.

Barrick fell 4.02% to $38.89 and UBS slipped 1.46% to $47.15. UBS reports Oct. 28; Barrick reports Nov. 9.

ASML fell 3.94% to $1,650 on its report day and was at $1,637.99 after hours. EPS of $14.65 beat the $12.17 estimate, while revenue of $13.05 billion narrowly missed $13.14 billion. Full-year 2026 guidance rose to 44 billion to 45 billion euros.

With an October 28 hike now more likely, rate sensitivity is setting the tape.

Originally published on the Position Tracker Substack. Read on Substack ↗

Track your live portfolio alongside our daily institutional research

Connect your brokerage in 60 seconds and get full access to Position Tracker Substack research inside your dashboard.

Start your free trial →